The South African Health Products Regulatory Authority (SAHPRA) has sought to assure the country that the anti-cancer medications sold or distributed in the country, meets the relevant health standard.
The authority was reacting to a report of the Lancet Global Health 2025; 13: e1250, an investigational study and its findings on substandard anti-cancer medications in Sub-Saharan African countries, including Ethiopia, Kenya, Malawi, and Cameroon.
According to SAHPRA spokesperson, Yuven Gounden, the study did not include South Africa.
“The seven medicines/dosage forms mentioned in the study are cisplatin, oxaliplatin, methotrexate, doxorubicin, cyclophosphamide, ifosfamide, and leucovorin.
The specific brands mentioned/shown in the article are neither registered nor marketed in South Africa,” said Gounden.
SAHPRA is tasked with regulating, monitoring, evaluating, investigating, inspecting and registering all health products, and Gounden emphasized that all medications imported in the country, undergo rigorous test.
“SAHPRA, in terms of the Medicines and Related Substances Act 101 of 1965, as amended, and its General Regulations, requires medicines marketed in the country to meet prescribed requirements and adhere to set standards.
Every batch of medicine produced must undergo testing to ensure that the integrity of the product is consistent with approved specifications before the release for sale, and imported medicines must additionally comply with the Guideline for Post-Importation Testing.
SAHPRA commenced internal processes to verify whether any of the South African-registered cancer medicines with the mentioned Active Pharmaceutical Ingredients (API) might have been affected or implicated,” explained Gounden.
Furthermore, the spokesperson highlighted that the cancer products registered and marketed in the country were not implicated or affected by the investigational study and its findings on substandard anti-cancer medicines.
SAHPRA CEO, Dr Boitumelo Semete-Makokotlela, echoed Gounden remarks, adding that their satisfied that the marketed and registered cancer medicines meet the appropriate specifications.
“SAHPRA is committed to the three pillars of quality, safety, and efficacy.
I am satisfied that our rigorous regulatory processes have borne fruit and that all patients, especially cancer patients, can rest assured that their health and well-being are not compromised,” remarked Semete-Makokotlela.
